HELPFUL INFO.
Search the Internet and
HELP NSTA
Support the NSTA while searching on the internet.
By using GoodSearch.com [Powered by Yahoo] to search the Internet, money goes
to the NSTA.
Dissertation on "Cervical Dystonia and the Black Community."
February 15, 2012
My name is Karen Chandler and I have cervical dystonia. I was born in Panama (Afro-Hispanic and I do not speak lick of Spanish, lol)and raisedin California, Michigan, and Florida. I was diagnosed with CD while I was in the Navy in 1998, when I was 27 years old. I was fitness fanatic, always at the gym. Then CD hit me like a ton of bricks... READ MORE...
Merz Pharmaceuticals Receives J-Code For Xeomin (incobotulinumtoxinA)
Merz Pharmaceuticals Receives J-Code For Xeomin (incobotulinumtoxinA)
January 10, 2012
Permanent Product-Specific Code Will Help Simplify Billing And Reimbursement
GREENSBORO, N.C., January 4, 2012 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced
that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare
Common Procedure Coding System (HCPCS) billing code, J0588 "INJECTION,
INCOBOTULINUMTOXIN A, 1 UNIT" for Xeomin® (incobotulinumtoxinA), effective beginning January 1,
2012. READ MORE...
2011 NSTA Symposium Information - Las Vegas, Nevada - October 22nd and 22rd
December 5, 2011
The 2011 NSTA symposium in Las Vegas, Nevada has passed and I am happy to report it was a huge success! We had over 130 people in attendance and the room was packed! We had so many people registering at the symposium as "walk ins", after the first presentation by Dr. Mayank Pathak, we had a short break so the banquet crew at Bally's Hotel and Casino could add another row of tables and chairs to accommodate everyone.
The feedback I have received was very positive! Everyone who attended enjoyed the presentations made by the guest speakers and commented on how easy it was to take in the information. I thank our guest speakers for taking the time out of their hectic schedule to join us and prepare their presentations in a way that everyone can comprehend. Just because we received positive feedback does not mean that we are not going to do our best to make more improvements. One of the goals of the NSTA is to provide information. We will continue to get information to you, people who are recently diagnosed and people who do not know they have this movement disorder in the most practical and efficient ways... READ MORE...
Programs Feature Simple Enrollment and Meaningful Financial Assistance
June 28, 2011
Allergan, Inc. is seeking patients who are or will be receiving onabotulinumtoxinA injections for the treatment of cervical dystonia for potential observational study participation.
Eligible patients may receive a patient stipend for their participation... READ MORE...
Merz Pharmaceuticals Joins Patient Advocates To Raise Awareness Of Cervical Dystonia and Blepharospasm
April 27, 2011
"Make Your Mark" Campaign Debuts Today
Visit www.MakeYourMarkCampaign.com to Make Your Mark
Greensboro, N.C., April 14 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates the inspirational stories of people living with blepharospasm or cervical dystonia (CD), also known as spasmodic torticollis, and aims to raise awareness of these often debilitating conditions... READ MORE...
"Ipsen Observational Registry Study"
March 9, 2011
Ipsen, manufacturer of DysportTM for Injection (also known in the US as abobotulinumtoxinA neurotoxin), is contacting physicians to conduct an observational registry study... READ MORE...
"Merz Pharmaceuticals Introduces Comprehensive Programs To Provide Patients WIth Financial Assistance For Xeomin® (incobotulinumtoxinA)"
March 8, 2011
Programs Feature Simple Enrollment And Meaningful Financial Assistance
Greensboro, N.C., March 8, 2011/PRNewswire/ - Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum toxin type A free from accessory proteins that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients. XEOMIN is also approved for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox®).READ MORE...